Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Accumulated Expenses (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Other Accumulated Expenses for 13 consecutive years, with $10.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses rose 2402.55% year-over-year to $10.8 million, compared with a TTM value of $10.8 million through Sep 2025, up 2402.55%, and an annual FY2025 reading of $10.8 million, up 2402.55% over the prior year.
  • Other Accumulated Expenses was $10.8 million for Q3 2025 at Arrowhead Pharmaceuticals, up from $7.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $10.8 million in Q3 2025 and bottomed at $17000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 4 years is $3.8 million, with a median of $435000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses decreased 1.52% in 2021, then surged 2402.55% in 2025.
  • Year by year, Other Accumulated Expenses stood at $17000.0 in 2021, then surged by 2458.82% to $435000.0 in 2023, then fell by 0.69% to $432000.0 in 2024, then soared by 2402.55% to $10.8 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ARWR at $10.8 million in Q3 2025, $7.4 million in Q2 2025, and $432000.0 in Q3 2024.